News | May 13, 2021
COVAXIN phase II/III clinical trial approved for 2-18 years
BBIL had proposed to carry out Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years
BBIL had proposed to carry out Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years
Jubilant successfully challenged Bracco's patent infringement claims in an Inter Parties Review (IPR) proceeding before the U.S. Patent Office
Glucon-D, Sugar Free, EverYuth Scrub, Peel Off Face Mask and Nycil maintained their leadership positions in-their respective categories as on March 2021.
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
Production of Sputnik V at Panacea Biotec sites will help facilitate global supply of Sputnik V to international partners of RDIF
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
India produces 60% of the world’s vaccine
Lonza Specialty Ingredients has become LifeClean’s first strategic industrial partner.
Building upon the momentum gained by pharma sector during the pandemic, Indian Pharmaceutical Alliance is leaving no stone unturned to create a faster road to recovery.
Subscribe To Our Newsletter & Stay Updated
